m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT05149
 [1], [2]
Non-coding RNA miR-103-3p METTL14  lncRNA       miRNA   circRNA Direct Inhibition m6A modification HNF1A HNF1A METTL14 Methylation : m6A sites
m6A Modification:
m6A Regulator Methyltransferase-like 14 (METTL14) WRITER
 Regulator Info 
m6A Target Hepatocyte nuclear factor 1-alpha (HNF1A/TCF1)
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type Non-coding RNA (ncRNA)
Epigenetic Regulator hsa-miR-103-3p microRNA View Details
Regulated Target Methyltransferase-like protein 14 (METTL14) View Details
Crosstalk Relationship ncRNA  →  m6A Inhibition
Crosstalk Mechanism ncRNAs directly impacts m6A modification through modulating the expression level of m6A regulator
Crosstalk Summary hsa-miR-103-3p targets the m6 A methyltransferase METTL14 to inhibit osteoblastic bone formation.METTL14 plays a protective role against OP by promoting the Hepatocyte nuclear factor 1-alpha (HNF1A/TCF1)/RUNX2 axis.
Responsed Disease Osteoporosis ICD-11: FB83.1
 Disease Info 
In-vitro Model
 MC3T3-E1 Normal Mus musculus CVCL_0409
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
Hepatocyte nuclear factor 1-alpha (HNF1A/TCF1) 1 Compound(s) Regulating the Target Click to Show/Hide the Full List
 Compound Name Norleucine Phase 1/2 [3]
Synonyms
L-Norleucine; 327-57-1; H-Nle-OH; (S)-2-Aminohexanoic acid; Glycoleucine; Caprine; L-(+)-Norleucine; L-2-Aminohexanoic acid; 2-Aminocaproic acid; L-2-Aminohexanoate; L-Aminohexanoate; alpha-Aminocaproic acid; (2S)-2-aminohexanoic acid; (S)-(+)-2-Aminohexanoic acid; Norleucine (VAN); L-Aminohexanoic acid; Hexanoic acid, 2-amino-, (S)-; 2S-amino-hexanoic acid; (S)-2-Aminocaproic acid; (S)-Norleucine; NSC 10378; L(+)-Norleucine; UNII-832C8OV84S; EINECS 206-321-4; BRN 1721750; NLE; CHEBI:18347; LRQKBLKVPFOOQJ-YFKPBYRVSA-N
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 21236
TTD: D00EFT
DrugBank: DB15458
References
Ref 1 MiR-103-3p targets the m(6) A methyltransferase METTL14 to inhibit osteoblastic bone formation. Aging Cell. 2021 Feb;20(2):e13298. doi: 10.1111/acel.13298. Epub 2021 Jan 13.
Ref 2 METTL14 upregulates TCF1 through m6A mRNA methylation to stimulate osteogenic activity in osteoporosis. Hum Cell. 2023 Jan;36(1):178-194. doi: 10.1007/s13577-022-00825-y. Epub 2022 Nov 19.
Ref 3 The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. doi: 10.1093/nar/28.1.235.